ClinicalTrials.gg
RecruitingNCT06017661Updated Sep 29, 2023

Investigation of a Polyphenol-rich Preparation as Support for Oncology Patients Undergoing Gastrointestinal Tumor Resection

An interventional study of Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds and Nutridrink Skin Repair in Immunomodulation, sponsored by AronPharma Sp. z o. o.. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by AronPharma Sp. z o. o. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of the study is to demonstrate, under clinical conditions, the effectiveness of the standard product 'Nutridrink' enriched with a mixture of plant extracts rich in polyphenolic compounds in the aspect of supporting the recovery of oncology patients undergoing surgical resection of tumours.

Read the detailed description

Oncology patients undergoing the procedure are exposed to various postoperative complications. Nutridrink with a mixture of extracts with anti-inflammatory and antioxidative properties aims to provide the patient with essential nutrients and bioactive substances that can reduce the inflammatory state, protect cells from oxidative damage, and decrease the risk of complications while supporting tissue healing processes after the surgical procedure. The study group are oncology patients undergoing surgical resection of gastrointestinal tumour. During the study, the effects of the mixture on levels of oxidative stress and inflammation markers will be assessed, as well as the subjective evaluation of patients' quality of life and well-being after surgical surgical tumor resection.

02

Conditions studied

  • Immunomodulation

Keywords

  • chokeberry
  • Nutridrink
  • immunomodulation
  • tumor resection
03

In context

Lead sponsor

AronPharma Sp. z o. o. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men, 18-80 years old
  • Patients diagnosed with resectable gastrointestinal tract cancer undergo the resection procedure no later than one month after being enrolled in the study
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Intake of supplements containing plant extracts, polyphenols or anthocyanins
  • Participation in another clinical trial
  • Inability to consume the product in liquid form as medication/placebo
  • Women who are pregnant, planning to become pregnant during the study or breastfeeding
  • disease, severe liver dysfunction, inflammatory bowel disease, tuberculosis, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplantation
  • /allergy to any of the ingredient
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds

    Group of 15 patients undergoing surgical resection of tumour

    Dietary Supplement: Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds

  • Active comparator
    Nutridrink Skin Repair

    Group of 15 patients undergoing surgical resection of tumour

    Dietary Supplement: Nutridrink Skin Repair

Interventions

  • Dietary supplementNutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds

    2 times a day

  • Dietary supplementNutridrink Skin Repair

    2 times a day

06

What researchers measure

Primary outcomes

  1. SOD level

    Comparison of SOD level

    Time frame: Baseline, 3 weeks, 6 weeks

  2. GSH level

    Comparison of GSH level

    Time frame: Baseline, 3 weeks, 6 weeks

  3. IL-6 level

    Comparison of IL-6 level

    Time frame: Baseline, 3 weeks, 6 weeks

  4. IL-8 level

    Comparison of IL-8 level

    Time frame: Baseline, 3 weeks, 6 weeks

Secondary outcomes

  1. Patients' quality of life

    Subjective assessment of patients' quality of life after surgical resection of the tumor (questionnaire). Higher scores mean a better outcome.

    Time frame: Baseline, 3 weeks, 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Uniwersyteckie Centrum Kliniczne, Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólne
    Gdańsk, 80-214, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Dec 2023, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Aug 30, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Dec 15, 2023
CompletionEst.
Dec 15, 2023
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06017661
Lead sponsor
AronPharma Sp. z o. o.
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Sep 1, 2023
Primary completion
Dec 15, 2023 (estimated)
Completion
Dec 15, 2023 (estimated)
Last update
Sep 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion